Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
EMERALD Chief Investigator Prof. Jonathan Fallowfield will present the poster on study design EMERALD is a multicentre Phase I/II study evaluating Resolution’s Regenerative Macrophage Therapy RTX001 in patients with end-stage liver disease taking place in the UK and Spain First patient dosed successfully, and safety cleared at Royal Infirmary of Edinburgh Edinburgh and London, UK, […]
